JP2020522529A - 癌の治療または予防のための薬剤およびその使用 - Google Patents

癌の治療または予防のための薬剤およびその使用 Download PDF

Info

Publication number
JP2020522529A
JP2020522529A JP2019567258A JP2019567258A JP2020522529A JP 2020522529 A JP2020522529 A JP 2020522529A JP 2019567258 A JP2019567258 A JP 2019567258A JP 2019567258 A JP2019567258 A JP 2019567258A JP 2020522529 A JP2020522529 A JP 2020522529A
Authority
JP
Japan
Prior art keywords
antigen binding
binding molecule
seq
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019567258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522529A5 (enExample
Inventor
ビル ダウガル
ビル ダウガル
ミシェル テン
ミシェル テン
エリザベス アハーン
エリザベス アハーン
マーク スミス
マーク スミス
Original Assignee
ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902125A external-priority patent/AU2017902125A0/en
Application filed by ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ, ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ filed Critical ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
Publication of JP2020522529A publication Critical patent/JP2020522529A/ja
Publication of JP2020522529A5 publication Critical patent/JP2020522529A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019567258A 2017-06-05 2018-06-05 癌の治療または予防のための薬剤およびその使用 Pending JP2020522529A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902125A AU2017902125A0 (en) 2017-06-05 "Agents for cancer therapy or prophylaxis and uses therefor"
AU2017902125 2017-06-05
PCT/AU2018/050557 WO2018223182A1 (en) 2017-06-05 2018-06-05 A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf- kb ligand) antagonist for cancer therapy or prophylaxis and uses therefor.

Publications (2)

Publication Number Publication Date
JP2020522529A true JP2020522529A (ja) 2020-07-30
JP2020522529A5 JP2020522529A5 (enExample) 2021-07-26

Family

ID=64565634

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019567258A Pending JP2020522529A (ja) 2017-06-05 2018-06-05 癌の治療または予防のための薬剤およびその使用

Country Status (7)

Country Link
US (1) US20230042913A1 (enExample)
EP (1) EP3634484A4 (enExample)
JP (1) JP2020522529A (enExample)
CN (1) CN111032085A (enExample)
AU (1) AU2018280340A1 (enExample)
CA (1) CA3065836A1 (enExample)
WO (1) WO2018223182A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024126750A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Methods for treating cancer

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
JP2022514215A (ja) * 2018-12-05 2022-02-10 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ Ｒａｎｋアンタゴニストおよびその使用
MX2021008121A (es) * 2019-01-03 2021-12-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer.
CN110179977A (zh) * 2019-05-22 2019-08-30 华中科技大学同济医学院附属同济医院 用于治疗黑色素瘤、肺癌或结直肠癌的组合药物制剂
CN114222586A (zh) * 2019-06-14 2022-03-22 斯克里普斯研究学院 免疫检查点阻断性双特异性分子
EP3999544A4 (en) * 2019-07-19 2023-08-09 Wuxi Xdc Singapore Private Limited POLYPEPTIDE COMPLEX FOR CONJUGATION AND ITS USE
CN110938652A (zh) * 2019-11-07 2020-03-31 浙江大学医学院附属第一医院 打靶载体及构建白喉毒素调控清除巨噬细胞的f4/80-dtr转基因小鼠的方法和应用
US12679900B2 (en) 2019-12-13 2026-07-14 Biosion Inc. Antibodies binding RANKL and uses thereof
MY202559A (en) * 2019-12-27 2024-05-08 Chugai Pharmaceutical Co Ltd Anti-ctla-4 antibody and use thereof
SE544000C2 (en) * 2020-03-17 2021-10-26 Xbrane Biopharma Ab Novel combination of tis sequence, signal peptide sequence and nucleic acid sequence encoding a recombinant protein
SE544001C2 (en) * 2020-03-17 2021-10-26 Xbrane Biopharma Ab Novel combination of tis sequences, signal peptide sequences and nucleic acid sequences encoding heavy and light chains of an antibody
CN111808198B (zh) * 2020-07-27 2022-06-03 广东安普泽生物医药股份有限公司 一种特异性结合rankl靶向治疗药物的抗体及其应用
TW202305009A (zh) * 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
US20240254245A1 (en) * 2021-05-12 2024-08-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
EP4353746A4 (en) * 2021-06-11 2024-12-04 Guangdong Fapon Biopharma Inc. Anti-pd-1 humanized antibody or antigen-binding fragment thereof and application thereof
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
CN118055946A (zh) * 2021-07-28 2024-05-17 科望(苏州)生物医药科技有限公司 新型多特异性分子
CN113929785B (zh) * 2021-09-10 2023-05-23 钦元再生医学(珠海)有限公司 一种可自分泌pd1-trem2双特异性抗体的嵌合抗原受体免疫细胞及其应用
AU2023347288A1 (en) 2022-09-23 2025-03-13 The University Of North Carolina At Chapel Hill Methods and compositions for the treatment of melanoma
TW202434288A (zh) * 2022-11-16 2024-09-01 大陸商蘇州盛迪亞生物醫藥有限公司 一種含抗ｒａｎｋｌ－ｎｇｆ雙特異性抗體的醫藥組成物
CN120418286A (zh) 2023-01-09 2025-08-01 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
IL327059A (en) * 2023-09-11 2026-05-01 Shanghai Btd Bio Tech Co Ltd A long-acting fusion protein that is an agonist for the parathyroid hormone receptor, and its use
CN122580572A (zh) * 2024-05-28 2026-08-14 北京量觉科技有限责任公司 免疫相关不良反应生物标志物及试剂盒

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
JP2011505848A (ja) * 2007-12-21 2011-03-03 エフ．ホフマン−ラ ロシュ アーゲー 二価の二重特異的抗体
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
JP2017506215A (ja) * 2013-12-30 2017-03-02 エピムアブ バイオセラピューティクス インコーポレイテ タンデム型Ｆａｂ免疫グロブリン及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104861067A (zh) * 2014-01-10 2015-08-26 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016166139A1 (en) * 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
JP7014724B2 (ja) * 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Ｆａｂ免疫グロブリンおよびその使用
DE202017007720U1 (de) * 2016-05-20 2025-02-11 Christoph Karl Pharmazeutische Zusammensetzungen mit Anti-RANKL-Antikörpern, Kalzium und Vitamin D, geeignet zur Behandlung und/oder Prophylaxe von Erkrankungen des Knochenstoffwechsels und von therapiebedingten Nebenwirkungen wie Hypokalzämien
MX2019002185A (es) * 2016-08-25 2019-09-19 Ai Therapeutics Inc Composiciones y metodos relacionados con la inhibicion de la señalizacion de rangos.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011505848A (ja) * 2007-12-21 2011-03-03 エフ．ホフマン−ラ ロシュ アーゲー 二価の二重特異的抗体
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
JP2017506215A (ja) * 2013-12-30 2017-03-02 エピムアブ バイオセラピューティクス インコーポレイテ タンデム型Ｆａｂ免疫グロブリン及びその使用
US20150307620A1 (en) * 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. CLIN. ONCOL. (2016) VOL.34, NO.12,P.E104-E106, JPN6022026190, ISSN: 0005193363 *
MABS (2016) VOL.8, NO.6, P.1010-1020, JPN6023010746, ISSN: 0005193364 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024126750A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Methods for treating cancer

Also Published As

Publication number Publication date
WO2018223182A1 (en) 2018-12-13
AU2018280340A1 (en) 2019-12-19
EP3634484A4 (en) 2022-01-12
US20230042913A1 (en) 2023-02-09
CN111032085A (zh) 2020-04-17
CA3065836A1 (en) 2018-12-13
EP3634484A1 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
US20230042913A1 (en) A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf-kb ligand) antagonist for cancer therapy or prophylaxis and uses thereof
JP6518370B2 (ja) Ｐｄ−１に対する抗体分子およびその使用
TWI772275B (zh) 特異性結合pd-1、tim-3或pd-1與tim-3之抗體及其用途
EP3116909B1 (en) Antibody molecules to lag-3 and uses thereof
KR20210015902A (ko) Psma 결합제 및 이의 용도
TW201827597A (zh) 利用嵌合抗原受體之癌症治療
KR20220116522A (ko) 증식성 질환의 치료를 위한 항-tgf-베타 항체 및 체크포인트 억제제의 용도
HK1225747A1 (en) Antibody molecules to pd-1 and uses thereof
US20220227876A1 (en) Rank antagonists and uses thereof
JP7712496B2 (ja) 抗ｃｄ３９抗体及びその使用
RU2788092C2 (ru) Молекулы антител к pd-1 и их применения
TW202304979A (zh) 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN117355333A (zh) 包含抗tm4sf1抗体和免疫治疗药剂的组合及其使用方法
HK40031258A (en) Antibody molecules to lag-3 and uses thereof
EA040861B1 (ru) Молекулы антител к pd-l1 и их применение
HK1229355A1 (en) Antibody molecules to lag-3 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230320

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230821

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231109